ArticleBMC cancer2025

Effect and safety of immunotherapy among elder patients (age ≥ 65) with recurrent or metastatic nasopharyngeal carcinoma.

Rui-Ling Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.